Drug intelligence / Profile preview

clobetasol + tacalcitol

Development stage: Unknown
Modality: Small Molecules
Administration: Topical

Overview

A combination therapy consisting of clobetasol (a potent topical corticosteroid) and tacalcitol (a vitamin D3 analog) used primarily for the treatment of nail psoriasis. The combination targets both the nail bed and nail matrix components of psoriasis. Typically, clobetasol is formulated as an 8% nail lacquer applied at bedtime on weekends, while tacalcitol ointment is applied under occlusion on the remaining days. This regimen has shown significant efficacy with the Nail Psoriasis Severity Index reduced by approximately 78% in clinical studies.

Targets

GR (Glucocorticoid receptor)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on clobetasol + tacalcitol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clobetasol + tacalcitol.

Explore the full profile